Freeline Therapeutics Holdings Performance
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
The firm shows a Beta (market volatility) of 1.09, which means a somewhat significant risk relative to the market. Freeline Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Freeline Therapeutics is expected to follow. Freeline Therapeutics right now shows a risk of 0.0%. Please confirm Freeline Therapeutics treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Freeline Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Freeline Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy essential indicators, Freeline Therapeutics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 67.1 M |
Freeline |
Freeline Therapeutics Relative Risk vs. Return Landscape
If you would invest 431.00 in Freeline Therapeutics Holdings on September 20, 2024 and sell it today you would earn a total of 0.00 from holding Freeline Therapeutics Holdings or generate 0.0% return on investment over 90 days. Freeline Therapeutics Holdings is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Freeline, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Freeline Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Freeline Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Freeline Therapeutics Holdings, and traders can use it to determine the average amount a Freeline Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| FRLN |
Based on monthly moving average Freeline Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Freeline Therapeutics by adding Freeline Therapeutics to a well-diversified portfolio.
Freeline Therapeutics Fundamentals Growth
Freeline Stock prices reflect investors' perceptions of the future prospects and financial health of Freeline Therapeutics, and Freeline Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Freeline Stock performance.
| Return On Equity | -1.01 | |||
| Return On Asset | -0.56 | |||
| Current Valuation | 2.78 M | |||
| Shares Outstanding | 4.36 M | |||
| Price To Book | 0.94 X | |||
| Price To Sales | 45.40 X | |||
| Revenue | 622 K | |||
| EBITDA | (64.84 M) | |||
| Cash And Equivalents | 90 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 5.92 M | |||
| Debt To Equity | 0.64 % | |||
| Book Value Per Share | 6.89 X | |||
| Cash Flow From Operations | (64.24 M) | |||
| Earnings Per Share | (11.40) X | |||
| Total Asset | 86.64 M | |||
| Retained Earnings | (445.35 M) | |||
About Freeline Therapeutics Performance
By examining Freeline Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Freeline Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Freeline Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Freeline Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 235 people.Things to note about Freeline Therapeutics performance evaluation
Checking the ongoing alerts about Freeline Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Freeline Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Freeline Therapeutics is not yet fully synchronised with the market data | |
| Freeline Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 622 K. Net Loss for the year was (49.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Freeline Therapeutics Holdings currently holds about 90 M in cash with (64.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. |
- Analyzing Freeline Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Freeline Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Freeline Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Freeline Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Freeline Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Freeline Therapeutics' stock. These opinions can provide insight into Freeline Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |